Here are seven details:
1. The nonprofit suggested learning more about its U.S. price and long-term success rates. The Institute for Clinical and Economic Review in Boston used the “quality-adjusted life year” assessment to evaluate the drugs.
2. ICER noted both drugs provide substantial clinical benefit while still having questions about the long-term effectiveness.
3. Spinraza is U.S.-approved and one of the most expensive drugs, costing $750,000 for the first year of use and $357,000 annually in the years following, according to the report. Patients who use the drug have experienced slow progression of the diseases. However, the drug is not a cure.
4. The ICER assessment estimated that Spinraza represents a cost of $728,000 per quality-adjusted life year, or year of healthy or near healthy life, for patients diagnosed with spinal muscular atrophy.
5. Novartis aims to find a cure for spinal muscular atrophy with its gene therapy. The drug Zolgensma is expected to earn U.S. approval in the first half of 2019. The company estimates the drug would be cost-effective at $4 million to $5 million as a one-time treatment. ICER estimated it at $2 million and said it represents a cost of $240,000 per quality-adjusted life year.
6. Treatments ranging between $100,000 and $150,000 per quality-adjusted life year are considered a good value. However, this can be a stretch for rare conditions and diseases.
7. It is unclear how payers will respond to the drugs hitting the market. Express Scripts told Reuters the Novartis estimated value would be “unsustainable.”
More articles on biologics:
Drs. Christopher Kaeding, David Flanigan perform 1st case with CartiHeal implant: 4 things to know
Biorez opens new offices in Connecticut: 3 things to know
Dr. James Bicos: Why biologics is so exciting for the future of orthopedics
